Publication: Rivaroxaban postmarketing risk of liver injury
Rivaroxaban postmarketing risk of liver injury
Date
Date
Date
Citations
Russmann, S., Niedrig, D. F., Budmiger, M., Schmidt, C., Stieger, B., Hürlimann, S., & Kullak-Ublick, G. A. (2014). Rivaroxaban postmarketing risk of liver injury. Journal of Hepatology, 61(2), 293–300. https://doi.org/10.1016/j.jhep.2014.03.026
Abstract
Abstract
Abstract
BACKGROUND: Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders. Although liver injury was observed in premarketing trials of rivaroxaban, there are no published postmarketing cases of liver injury associated with rivaroxaban. METHODS: Report of 14 cases of liver injury associated with rivaroxaban, including two with liver biopsy, and search queries in three large international pharmacovigilance databases for co
Additional indexing
Creators (Authors)
- Russmann, Stefan
- Niedrig, David F
- Budmiger, Mathias
- Schmidt, Caroline
- Stieger, Bruno
- Hürlimann, Sandra
- Kullak-Ublick, Gerd A
Volume
Volume
Volume
Number
Number
Number
Page Range
Page Range
Page Range
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Citations
Russmann, S., Niedrig, D. F., Budmiger, M., Schmidt, C., Stieger, B., Hürlimann, S., & Kullak-Ublick, G. A. (2014). Rivaroxaban postmarketing risk of liver injury. Journal of Hepatology, 61(2), 293–300. https://doi.org/10.1016/j.jhep.2014.03.026
